{"nctId":"NCT00095875","briefTitle":"Combination Chemotherapy and Radiation in Treating Patients With Stage III or IV Head and Neck Cancer (Paradigm Trial)","startDateStruct":{"date":"2004-08"},"conditions":["Head and Neck Cancer"],"count":145,"armGroups":[{"label":"Arm I","type":"EXPERIMENTAL","interventionNames":["Drug: carboplatin","Drug: cisplatin","Drug: docetaxel","Drug: fluorouracil"]},{"label":"Arm II","type":"EXPERIMENTAL","interventionNames":["Drug: cisplatin"]}],"interventions":[{"name":"carboplatin","otherNames":["Paraplatin"]},{"name":"cisplatin","otherNames":["Platinol"]},{"name":"docetaxel","otherNames":["Taxotere"]},{"name":"fluorouracil","otherNames":["Efudex"]}],"eligibilityModule":{"eligibilityCriteria":"List of Inclusion Criteria:\n\n* Histologically or cytologically confirmed squamous cell carcinoma of the head and neck\n\n  * Stage III or IV\\* disease\n  * One of the following primary tumor sites:\n\n    * Oral cavity\n\n      * No mandible invasion\n    * Oropharynx\n    * Hypopharynx\n    * Larynx\n  * The following primary tumor sites are excluded:\n\n    * Nasal cavity\n    * Paranasal cavity\n    * Nasopharynx NOTE: \\*No evidence of distant metastases by chest x-ray, abdominal ultrasound, or CT scan (for patients with liver function test abnormalities) or bone scan (for patients with local symptoms)\n* At least 1 uni- or bi-dimensionally measurable lesion\n\nPATIENT CHARACTERISTICS:\n\nAge\n\n* Over 18\n\nPerformance status\n\n* WHO 0-1\n\nLife expectancy\n\n* Not specified\n\nHematopoietic\n\n* Neutrophil count \\> 1,500/mm\\^3\n* Platelet count \\> 100,000/mm\\^3\n* Hemoglobin \\> 10 g/dL\n\nHepatic\n\n* Bilirubin normal\n* AST or ALT within eligibility range\n* Alkaline phosphatase within eligibility range\n\nRenal\n\n* Creatinine clearance \\> 60 mL/min\n\nCardiovascular\n\n* No unstable cardiac disease despite treatment\n* No myocardial infarction within the past 6 months\n\nPulmonary\n\n* No chronic obstructive pulmonary disease, defined as requiring hospitalization for pneumonia or respiratory decompensation within the past year\n\n  * Obstruction caused by the tumor allowed\n\nNeurologic\n\n* No symptomatic peripheral neuropathy \\> grade 2\n* No symptomatic altered hearing \\> grade 2\n* No history of significant neurologic or psychiatric disorders, including dementia or seizures\n\nOther\n\n* No active drug addiction, including alcohol, cocaine, or intravenous drugs within the past 6 months\n* No other malignancy within the past 5 years except adequately treated carcinoma in situ of the cervix, basal cell or squamous cell skin cancer, or other cancer curatively treated by surgery alone\n* No active, clinically significant, uncontrolled infection\n* No autoimmune disease requiring therapy\n* No unhealed or clinically active peptic ulcer disease\n* No hypercalcemia\n* No other serious illness or medical condition\n* No involuntary weight loss \\> 25% of body weight within the past 2 months\n* HIV negative\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception during and for at least 3 months after study participation\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\n* Not specified\n\nChemotherapy\n\n* No prior chemotherapy\n\nEndocrine therapy\n\n* Not specified\n\nRadiotherapy\n\n* No prior radiotherapy\n\nSurgery\n\n* No prior organ transplantation\n* No prior surgery for this cancer\n\n  * Biopsy allowed\n\nOther\n\n* More than 30 days since prior participation in another investigational study\n* No other concurrent anticancer therapy","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Overall Survival","description":"To compare the 3-year survival achieved by docetaxel/cisplatin/5-FU based sequential therapy with platinum based chemo radiotherapy in patients with locally advanced SCCHN. Overall survival is defined as the time from date of randomisation to death from any cause. Patients alive at the time of current analysis were censored at the date last known to be alive.Kaplan-Meier method was used to estimate overall survival","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"73","spread":null},{"groupId":"OG001","value":"78","spread":null}]}]}]},{"type":"SECONDARY","title":"Progression-free Survival and Disease-specific Survival as Assessed by Disease Progression or Death and Log Rank Tests at the Median, and 2, 3, and 5 Years","description":"Progression free survival was defined as the time from date of randomisation to disease progression or death from any cause without progression whichever occurred first; otherwise, patients were censored at the date last known to be free of progression.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67","spread":null},{"groupId":"OG001","value":"69","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":56,"n":70},"commonTop":["Xerostomia","Pain","Mucositis","Neuropathy"]}}}